| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2543928 | Journal of the American Pharmacists Association | 2006 | 11 Pages |
Abstract
Cardiovascular risk likely differs depending upon SGA choice, but limited data make it difficult to predict the metabolic changes associated with switching. Prospective controlled studies are needed to describe the cardiovascular consequences of switching among the antipsychotic agents so that evidence-based strategies can be developed for selection of the optimal SGA.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
L. Douglas PhD, Bernard T. PharmD, Joel R. McConkey, Michael A. MD, Larry M. PharmD,